171 related articles for article (PubMed ID: 37648672)
21. African American and Caucasian patients with Sézary syndrome have no differences in outcomes at an ethnically diverse urban medical center.
Martini DJ; Goyal S; Switchenko JM; Lechowicz MJ; Allen PB
Leuk Lymphoma; 2022 Sep; 63(9):2094-2101. PubMed ID: 35481397
[TBL] [Abstract][Full Text] [Related]
22. Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity.
Papadavid E; Kapniari E; Pappa V; Nikolaou V; Iliakis T; Dalamaga M; Jonak C; Porkert S; Engelina S; Quaglino P; Ortiz-Romero PL; Vico C; Cozzio A; Dimitriou F; Guiron R; Guenova E; Hodak E; Bagot M; Scarisbrick J
Br J Dermatol; 2021 Nov; 185(5):1035-1044. PubMed ID: 34137025
[TBL] [Abstract][Full Text] [Related]
23. Lack of Durable Remission with Conventional-Dose Total Skin Electron Therapy for the Management of Sezary Syndrome and Multiply Relapsed Mycosis Fungoides.
Campbell BA; Ryan G; McCormack C; Tangas E; Bressel M; Twigger R; Buelens O; van der Weyden C; Prince HM
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31717353
[TBL] [Abstract][Full Text] [Related]
24. The concurrent administration of imatinib with extracorporeal photopheresis leads to complete and durable responses in patients with refractory sclerotic type chronic graft-versus-host disease.
Alsuliman T; Magro L; Coiteux V; Gauthier J; Srour M; Lionet A; Beauvais D; Yakoub-Agha I
Curr Res Transl Med; 2020 Apr; 68(2):71-76. PubMed ID: 31631014
[TBL] [Abstract][Full Text] [Related]
25. What Does the Future Hold for Biomarkers of Response to Extracorporeal Photopheresis for Mycosis Fungoides and Sézary Syndrome?
Akilov OE
Cells; 2023 Sep; 12(18):. PubMed ID: 37759543
[TBL] [Abstract][Full Text] [Related]
26. Review of extracorporeal photopheresis in early-stage (IA, IB, and IIA) cutaneous T-cell lymphoma.
Miller JD; Kirkland EB; Domingo DS; Scull H; Jekutis B; Dallas M; Cooper KD; Baron ED
Photodermatol Photoimmunol Photomed; 2007 Oct; 23(5):163-71. PubMed ID: 17803594
[TBL] [Abstract][Full Text] [Related]
27. Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndrome.
McGirt LY; Thoburn C; Hess A; Vonderheid EC
Photodermatol Photoimmunol Photomed; 2010 Aug; 26(4):182-91. PubMed ID: 20626820
[TBL] [Abstract][Full Text] [Related]
28. [Sézary syndrome treated with extracorporeal photopheresis: Report of one case].
Molgó M; Jaque A; Vial V; Ocqueteau M; Pereira J; Chang M; González S
Rev Med Chil; 2015 Nov; 143(11):1449-58. PubMed ID: 26757870
[TBL] [Abstract][Full Text] [Related]
29. 75% Complete Response and 15% Partial Response to Extracorporeal Photopheresis Combined With Other Therapies in Resistant Early Stage Cutaneous T-Cell Lymphoma.
Seremet S; Abhyankar S; Herd TJ; Aires D
J Drugs Dermatol; 2016 Oct; 15(10):1212-1216. PubMed ID: 27741338
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment of Sezary syndrome with extracorporeal photopheresis - The first attempt in India.
Tiwari AK; Arora D; Dhiman P; Kapoor S; Aggarwal G; Dara RC; Vaid A
Asian J Transfus Sci; 2019; 13(1):66-69. PubMed ID: 31360016
[TBL] [Abstract][Full Text] [Related]
31. Evidence-based practice of photopheresis 1987-2001: a report of a workshop of the British Photodermatology Group and the U.K. Skin Lymphoma Group.
McKenna KE; Whittaker S; Rhodes LE; Taylor P; Lloyd J; Ibbotson S; Russell-Jones R; ;
Br J Dermatol; 2006 Jan; 154(1):7-20. PubMed ID: 16403088
[TBL] [Abstract][Full Text] [Related]
32. Real-world use of extracorporeal photopheresis for patients with cutaneous T-cell lymphoma in the United States: 2010-2015.
Ling YL; Huang X; Mitri G; Lovelace B; Pham A; Knobler R; Li X; Gao X
J Dermatolog Treat; 2020 Feb; 31(1):91-98. PubMed ID: 30892982
[No Abstract] [Full Text] [Related]
33. Alitretinoin in the treatment of cutaneous T-cell lymphoma.
Kaemmerer T; Stadler PC; Helene Frommherz L; Guertler A; Einar French L; Reinholz M
Cancer Med; 2021 Oct; 10(20):7071-7078. PubMed ID: 34435474
[TBL] [Abstract][Full Text] [Related]
34. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides.
Wilson LD; Jones GW; Kim D; Rosenthal D; Christensen IR; Edelson RL; Heald PW; Kacinski BM
J Am Acad Dermatol; 2000 Jul; 43(1 Pt 1):54-60. PubMed ID: 10863224
[TBL] [Abstract][Full Text] [Related]
35. Extracorporeal photopheresis in Sézary syndrome.
Russell-Jones R; Fraser-Andrews E; Spittle M; Whittaker S
Lancet; 1997 Sep; 350(9081):886. PubMed ID: 9310623
[No Abstract] [Full Text] [Related]
36. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.
Geskin L
Skin Therapy Lett; 2007 Jun; 12(5):1-4. PubMed ID: 17609808
[TBL] [Abstract][Full Text] [Related]
37. Photopheresis in cutaneous T-cell lymphoma: five-year experience.
Crovetti G; Carabelli A; Berti E; Guizzardi M; Fossati S; De Filippo C; Bertani E
Int J Artif Organs; 2000 Jan; 23(1):55-62. PubMed ID: 12118838
[TBL] [Abstract][Full Text] [Related]
38. Extracorporeal photopheresis for the treatment of early-stage mycosis fungoides.
Lewis DJ; Duvic M
Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28338261
[TBL] [Abstract][Full Text] [Related]
39. The role of extracorporeal photopheresis in the treatment of cutaneous T-cell lymphomas.
Atta M; Papanicolaou N; Tsirigotis P
Transfus Apher Sci; 2012 Apr; 46(2):195-202. PubMed ID: 22067605
[TBL] [Abstract][Full Text] [Related]
40. Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol.
Arulogun S; Prince HM; Gambell P; Lade S; Ryan G; Eaton E; McCormack C
J Am Acad Dermatol; 2008 Oct; 59(4):589-95. PubMed ID: 18656282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
